Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Illumina, Inc. — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $29.97, while Illumina, Inc. trades at $193.06 (market cap $28.96B). Which is the better fit depends on your goals.
| DBC | ILMN | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $31.69 | $205.10 |
52-Week Low | $21.62 | $91.00 |
Market Cap | — | $28.96B |
Enterprise Value | — | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $28.91, up 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. Financial ratios are unavailable in the provided data. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.
The outlook for DBC is clouded by bearish technicals and lack of fundamental data. Commodity market volatility from geopolitical tensions offers potential upside, but investors face risks from unclear financial health and market sentiment shifts. Careful evaluation of upcoming earnings and analyst coverage is essential.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
